TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglial receptor that recognizes changes in the lipid microenvironment, which may occur during amyloid β (Aβ) accumulation and neuronal degeneration in Alzheimer’s disease (AD). Rare TREM2 variants that affect TREM2 function lead to an increased risk of developing AD. In murine models of AD, TREM2 deficiency prevents microglial clustering around Aβ deposits. However, the origin of myeloid cells surrounding amyloid and the impact of TREM2 on Aβ accumulation are a matter of debate. Using parabiosis, we found that amyloid-associated myeloid cells derive from brain-resident microglia rather than from recruitment of peripheral blood monocytes. To determine the impact of TREM2 deficiency on Aβ accumulation, we examined Aβ plaques in the 5XFAD model of AD at the onset of Aβ-related pathology. At this early time point, Aβ accumulation was similar in TREM2-deficient and -sufficient 5XFAD mice. However, in the absence of TREM2, Aβ plaques were not fully enclosed by microglia; they were more diffuse, less dense, and were associated with significantly greater neuritic damage. Thus, TREM2 protects from AD by enabling microglia to surround and alter Aβ plaque structure, thereby limiting neuritic damage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“loss of TREM2 function in AD mouse models restricts the ability of microglia to surround Aβ plaques15,16, proliferate, and convert to DAM10,15,17, which in turn leads to more profound neuritic dystrophy18,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“which may represent dystrophic neurons that accumulate over time as a result of ineffective microglial control of AD pathology due to lack of Trem218,19.”
From Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the compaction of protofibrillary Aβ into a dense core plaque, which requires apoE and is promoted by TREM2 (Bales et al., 1997b, 1999; Bien-Ly et al., 2012; Wang et al., 2016; Yuan et al., 2016), could be a protective mechanism that limits neurotoxicity of amyloid deposits once they start to build up in the aging brain.”
From Microglia in Alzheimer’s disease (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trem2 deficiency induces dynamic changes but an eventual increase in plaque and neuritic pathology (Jay et al., 2017; Wang et al., 2015; Wang et al., 2016; Yuan et al., 2016).”
From Elevated TREM2 Gene Dosage Reprograms Microglia Responsivity and Ameliorates Pathological Phenotypes in Alzheimer’s Disease Models (2018) · cites this paper as Wang et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lack of TREM2 results in impaired plaque trimming, which leads to enlarged plaques with reduced compaction48,49.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [48]
Experimental — accuracy not yet measured
42 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., Griep, A., Axt, D., Remus, A., Tzeng, T.-C., et al. (2013) · Nature · doi:10.1038/nature11729 · Cited by 2,898 · cited 4×
“Brains were isolated 3 h after injection and made into single-cell suspension as previously described (Heneka et al., 2013).”
BackgroundMethodInfluentialIdentification of a unique TGF-β–dependent molecular and functional signature in microglia
Butovsky, O., Jedrychowski, M. P., Moore, C. S., Cialic, R., Lanser, A. J., Gabriely, G., Koeglsperger, T., Dake, B., Wu, P. M., Doykan, C. E., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3599 · Cited by 2,543 · cited 1×
“However, phenotypic markers of migroglia, such as low expression of CD45 and high expression of the P2Y(12) receptor, are altered upon microglial activation and therefore do not precisely discriminate microglia from monocytes (Butovsky et al., 2014).”
BackgroundTREM2 Lipid Sensing Sustains the Microglial Response in an Alzheimer’s Disease Model
Wang, Y., Cella, M., Mallinson, K., Ulrich, J. D., Young, K. L., Robinette, M. L., Gilfillan, S., Krishnan, G. M., Sudhakar, S., Zinselmeyer, B. H., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.049 · Cited by 1,736 · cited 11×
“…response to Aβ deposits in all AD models, changes in Aβ burden develop more slowly; therefore, the discrepancies in Aβ accumulation may be a result of the varied timing of the analyses—8 mo in 5XFAD mice (Wang et al., 2015) and 3–4 mo in APP PS1-21 mice (Ulrich et al., 2014; Jay et al., 2015).”
BackgroundMethodResultInfluentialSelf-citationAlzheimer’s Disease: The Challenge of the Second Century
Holtzman, D. M., Morris, J. C., & Goate, A. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002369 · Cited by 1,424 · cited 1×
“Key pathological features of AD consist of the deposition of amyloid-β peptide (Aβ) and hyperphosphorylated tau aggregates that, together, are linked with synapse loss and neuronal cell death, as well as activation of microglia and astrocytes (Holtzman et al., 2011).”
BackgroundSelf-citationAlzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357 · cited 1×
“Recent genome-wide association studies have identified rare variants of genes that encode immune receptors as risk factors (Guerreiro and Hardy, 2014; Karch and Goate, 2015).”
BackgroundMicroglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease
Prinz, M., & Priller, J. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3722 · Cited by 1,329 · cited 1×
“Given that brain-resident microglia are capable of self-renewal and expansion (Gomez Perdiguero et al., 2013; Greter and Merad, 2013; Prinz and Priller, 2014), we next sought to determine if microglia associated with plaques resulted from the proliferation of resident microglia.”
BackgroundTakahashi, K., Rochford, C. D. P., & Neumann, H. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041611 · Cited by 1,124 · cited 2×
“TREM2 signaling promotes survival, proliferation, phagocytosis, and secretion of cytokines and chemokines (Takahashi et al., 2005; Otero et al., 2009; Wang et al., 2015).”
BackgroundThe Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727 · cited 2×
“The origin of nonfamilial AD is less well understood and may depend on a combination of genetic and nongenetic risk factors (Tanzi, 2012).”
Background
Cited by
Items 301–400 of 838
The Dominantly Inherited Alzheimer Network (DIAN), Li, Z., Del-Aguila, J. L., Dube, U., Budde, J., Martinez, R., Black, K., Xiao, Q., Cairns, N. J., Dougherty, J. D., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0551-4 · Cited by 56
Regulation of microglia population dynamics throughout development, health, and disease
Hammond, B. P., Manek, R., Kerr, B. J., Macauley, M. S., & Plemel, J. R. (2021) · Glia · doi:10.1002/glia.24047 · Cited by 65
“One such risk factor is the R47H mutation in the gene for triggering receptor expressed on myeloid cells 2 (TREM2) (Colonna & Wang, 2016; Guerreiro et al., 2013; Jonsson et al., 2013).”
BackgroundMicroglial Immunometabolism in Alzheimer’s Disease
Shippy, D. C., & Ulland, T. K. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.563446 · Cited by 54
“…function, and participate in AD (Lue et al., 2010; Ulrich et al., 2014, 2017; Condello et al., 2015; Vincenti et al., 2015; Wang Y. et al., 2015; Wang et al., 2016; Ulrich and Holtzman, 2016; Yuan et al., 2016; Keren-Shaul et al., 2017; Ulland et al., 2017; Gotzl et al., 2019; Mathys et al.,…”
BackgroundSelf-citationGómez-Arboledas, Á., Carvalho, K., Balderrama-Gutierrez, G., Chu, S., Liang, H. Y., Schartz, N. D., Selvan, P., Petrisko, T. J., Pan, M. A., Mortazavi, A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01416-6 · Cited by 61
Nirzhor, S. S. R., Khan, R. I., & Neelotpol, S. (2018) · Biomolecules · doi:10.3390/biom8030093 · Cited by 61
“Furthermore, several recent studies involving TREM2-deficient mice show that such deficiency may lead to a marked increase in Aβ-induced pathology [6,24,112,113].”
BackgroundUnderstanding microglial diversity and implications for neuronal function in health and disease
De Schepper, S., Crowley, G., & Hong, S. (2021) · Developmental Neurobiology · doi:10.1002/dneu.22777 · Cited by 57
“…amyloid plaque pathology (Kleinberger et al., 2017; Ulland et al., 2017; Wang et al., 2015), a phenotype also demonstrated in human AD brain tissue (Toomey et al., 2020; Ulrich et al., 2014; Wang et al., 2016) (for a recent review on TREM2, please refer to: Deczkowska, Weiner, & Amit, 2020).”
BackgroundLILRB2-mediated TREM2 signaling inhibition suppresses microglia functions
Zhao, P., Xu, Y., Jiang, L.-L., Fan, X., Ku, Z., Li, L., Liu, X., Deng, M., Arase, H., Zhu, J.-J., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00550-y · Cited by 54
“Microglia, brain-resident myeloid cells, play pivotal roles in AD development by regulating brain homeostasis [8] and neuroinflammation [9], promoting Aβ plaque phagocytic clearance [10], and clustering and limiting diffusion of Aβ plaques [11] and tau tangles [12].”
BackgroundWang, P., Yang, P., Qian, K., Li, Y., Xu, S., Meng, R., Guo, Q., Cheng, Y., Cao, J., Xu, M., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121360 · Cited by 58
Disease-associated microglia in neurodegenerative diseases: Friend or foe?
Cheng, Y.-H., & Ho, M. S.-C. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3003426 · Cited by 64
Xue, D., Tabib, T., Morse, C., & Lafyatis, R. (2019) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2019.11.012 · Cited by 58
Karahan, H., Smith, D. C., Kim, B., Dabin, L. C., Al-Amin, M. M., Wijeratne, H. R. S., Pennington, T., Viana di Prisco, G., McCord, B., Lin, P. B.-C., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe3954 · Cited by 53
Regulation of α-synuclein homeostasis and inflammasome activation by microglial autophagy
Choi, I., Heaton, G. R., Lee, Y.-K., & Yue, Z. (2022) · Science Advances · doi:10.1126/sciadv.abn1298 · Cited by 58
Michno, W., Kaya, I., Nyström, S., Guérard, L., Nilsson, K. P. R., Hammarström, P., Blennow, K., Zetterberg, H., & Hanrieder, J. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b01361 · Cited by 55
“implicated in AD pathology as it was shown to mediate early microglia response and limits neuritic damage of Aβ since TREM2 knock-out mice were found to display accelerated Aβ accumulation, plaque pathology, and defects in microglia activity (59).”
BackgroundNAKAI, T., Yamada, K., & Mizoguchi, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115549 · Cited by 53
Role of TREM2 in Alzheimer’s Disease: A Long Road Ahead
Kulkarni, B., Kumar, D., Martins, N. A., & Sellamuthu, S. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02477-9 · Cited by 54
“TREM2 is involved in Aβ pathology regulation [36, 37], hyperphosphorylation of tau protein [38–40], and microglial activation [2, 41–44].”
BackgroundComparative Review of Microglia and Monocytes in CNS Phagocytosis
Andoh, M., & Koyama, R. (2021) · Cells · doi:10.3390/cells10102555 · Cited by 62
Wu, X., Saito, T., Saido, T. C., Barron, A. M., & Ruedl, C. (2021) · eLife · doi:10.7554/elife.71879 · Cited by 49
Tan, Y. J., Ng, A. S. L., Vipin, A., Lim, J. K. W., Chander, R. J., Ji, F., Qiu, Y., Ting, S. K. S., Hameed, S., Lee, T.-S., et al. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161277 · Cited by 55
Penney, J., Ralvenius, W. T., Loon, A., Cerit, O., Dileep, V., Milo, B., Pao, P., Woolf, H., & Tsai, L. (2024) · Glia · doi:10.1002/glia.24485 · Cited by 52
“In AD mouse models, TREM2 knockout impairs the ability of microglia to sense and respond to amyloid plaques, also resulting in detrimental effects in tau models (Gratuze et al., 2020; Keren-Shaul et al., 2017; Lee et al., 2021; Leyns et al., 2017; Wang et al., 2015, 2016).”
BackgroundSchmöle, A., Lundt, R., Toporowski, G., Hansen, J. N., Beins, E. C., Halle, A., & Zimmer, A. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180230 · Cited by 54
The role of glia in protein aggregation
Li, Q., & Haney, M. S. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105015 · Cited by 52
Crosstalk between Microglia and Neurons in Neurotrauma: An Overview of the Underlying Mechanisms
Shaito, A. A., Kobeissy, F. H., Haidar, M. A., Ibeh, S., Shakkour, Z., Reslan, M. A., Nwaiwu, J. I., Moqidem, Y. A., Sader, G., Nickles, R. G., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666211202123322 · Cited by 58
“Several studies have shown that in AD, TREM-2 deficient microglia showed less effective Aβ internalization [151-154].”
Tran, K. M., Kawauchi, S., Kramár, E. A., Rezaie, N., Liang, H. Y., Sakr, J. S., Gomez-Arboledas, A., Arreola, M. A., Cunha, C. D., Phan, J., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00598-4 · Cited by 50
“Consistent with the R47H variant inferring a loss-of-function phenotype, the initial microglia-plaque interaction is impaired, resulting in smaller and less compacted plaques yet an increase in dystrophic neurites produced by those plaques, in line with prior data from Trem2 KO mice [61, 62, 68].”
Ma, Y., Hu, X., Karako, K., Song, P., Tang, W., & Xia, Y. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1576020 · Cited by 54
The role of TREM2 in Alzheimer’s disease: from the perspective of Tau
Huang, W., Huang, J., Huang, N., & Luo, Y. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1280257 · Cited by 49
Effect of APOE alleles on the glial transcriptome in normal aging and Alzheimer’s disease
Serrano-Pozo, A., Li, Z., Noori, A., Nguyen, H. N., Mezlini, A., Li, L., Hudry, E., Jackson, R. J., Hyman, B. T., & Das, S. (2021) · Nature Aging · doi:10.1038/s43587-021-00123-6 · Cited by 49
Tipping points in neurodegeneration
Simons, M., Levin, J., & Dichgans, M. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.031 · Cited by 50
“DAM proliferate in the vicinity of amyloid plaques, where they participate in Ab phagocytosis and plaque compaction, thereby reducing amyloid burden and limiting the spread of toxic species.(53,93,94) Even if there are conditions in which TREM2 can mediate maladaptive and detrimental microglia functions, it appears th…”
Neocortical and hippocampal TREM2 protein levels during the progression of Alzheimer's disease
Perez, S. E., Nadeem, M., He, B., Miguel, J. C., Malek-Ahmadi, M. H., Chen, K., & Mufson, E. J. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.02.012 · Cited by 49
“TREM2 or DAP12 deficiency leads to an increase in plaques not fully enclosed by microglial and dystrophic profiles (Wang et al., 2016; Yuan et al., 2016).”
BackgroundIn Vivo Imaging of Microglia With Multiphoton Microscopy
Hierro-Bujalance, C., Bacskai, B. J., & Garcia-Alloza, M. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00218 · Cited by 46
“However, in TREM2 deficient mice Aβ plaques are not fully enclosed by microglia and are associated with significantly greater neuritic damage (Wang et al., 2016).”
BackgroundInfluentialAfrican Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants
Schindler, S. E., Cruchaga, C., Joseph, A., McCue, L., Farias, F. H. G., Wilkins, C. H., Deming, Y., Henson, R. L., Mikesell, R. J., Piccio, L., et al. (2021) · Neurology Genetics · doi:10.1212/nxg.0000000000000571 · Cited by 49
Self-citationMcFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
Deming, Y., Li, Z., Benitez, B. A., & Cruchaga, C. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1486823 · Cited by 48
Ruiz de Martín Esteban, S., Benito-Cuesta, I., Terradillos, I., Martínez-Relimpio, A. M., Arnanz, M. A., Ruiz-Pérez, G., Korn, C., Raposo, C., Sarott, R. C., Westphal, M. V., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841766 · Cited by 45
“A similar effect has been described in TREM2-lacking mice, suggesting an impairment in microglial function (Wang et al., 2016).”
BackgroundAβ and Tau Regulate Microglia Metabolism via Exosomes in Alzheimer’s Disease
Zhao, Y., Liu, B., Wang, J., Xu, L., Yu, S., Fu, J., Yan, X., & Su, J. (2022) · Biomedicines · doi:10.3390/biomedicines10081800 · Cited by 53
Deficiency of a sulfotransferase for sialic acid-modified glycans mitigates Alzheimer’s pathology
Zhang, Z., Takeda‐Uchimura, Y., Foyez, T., Ohtake‐Niimi, S., Narentuya, Akatsu, H., Nishitsuji, K., Michikawa, M., Wyss‐Coray, T., Kadomatsu, K., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1615036114 · Cited by 53
Caspase-8, association with Alzheimer’s Disease and functional analysis of rare variants
Rehker, J., Rodhe, J., Nesbitt, R. R., Boyle, E. A., Martin, B. K., Lord, J., Karaca, I., Naj, A., Jessen, F., Helisalmi, S., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0185777 · Cited by 47
Mechanistic insights into the deleterious roles of Nasu-Hakola disease associated TREM2 variants
Dash, R., Choi, H. J., & Moon, I. S. (2020) · Scientific Reports · doi:10.1038/s41598-020-60561-x · Cited by 49
Rong, Z., Cheng, B., Zhong, L., Ye, X., Li, X., Jia, L., Li, Y., Shue, F., Wang, N., Cheng, Y., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202000550rr · Cited by 46
Doustar, J., Rentsendorj, A., Torbati, T., Regis, G. C., Fuchs, D.-T. S., Sheyn, J., Mirzaei, N., Graham, S. L., Shah, P. K., Mastali, M., et al. (2020) · Aging Cell · doi:10.1111/acel.13246 · Cited by 47
“These plaque subtypes were previously implicated in triggering neuroinflammation and increased neurotoxicity (Busche et al., 2008; Koffie et al., 2009; Li et al., 2020; Rasmussen et al., 2017; Selkoe, 2008; Shankar et al., 2008; Wang et al., 2016).”
BackgroundAlzheimer’s genes in microglia: a risk worth investigating
Sudwarts, A., & Thinakaran, G. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00679-4 · Cited by 44
“In addition to its requirement for the phenotypic transition from Stage I to Stage II DAM [10], TREM2 is also necessary for the local proliferation of microglia near amyloid deposits [41].”
BackgroundRao, A. T., Chen, N., Kim, M. J., Blumenfeld, J. R., Yip, O., Liang, Z., Shostak, D. M., Hao, Y., Nelson, M. R., Koutsodendris, N., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.10.005 · Cited by 49
Central Nervous System Macrophages in Health and Disease
Hove, H. V., Feo, D. D., Greter, M., & Becher, B. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082423-041334 · Cited by 53
Singh, A. K., Mishra, G., Maurya, A., Awasthi, R., Kumari, K., Thakur, A., Rai, A., Rai, G. K., Sharma, B., Kulkarni, G. T., et al. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190903102822 · Cited by 48
Peroxiredoxin 6 mediates protective function of astrocytes in Aβ proteostasis
Pankiewicz, J. E., Diaz, J. R., Martá-Ariza, M., Lizińczyk, A. M., Franco, L. A., & Sadowski, M. J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00401-8 · Cited by 45
“These differences likely reflect differential effect of Prdx6 gene dosage on phagocytic activity of periplaque microglia and resulting degree of plaque diffusion [36].”
BackgroundInfluentialGenetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
TREM2 is down-regulated by HSV1 in microglia and involved in antiviral defense in the brain
Fruhwürth, S., Reinert, L. S., Öberg, C., Sakr, M., Henricsson, M., Zetterberg, H., & Paludan, S. R. (2023) · Science Advances · doi:10.1126/sciadv.adf5808 · Cited by 40
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease
Tenner, A. J., & Petrisko, T. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01073-y · Cited by 55
“Although the biology of TREM2 is complex 135–138 , this impact of both C1q and TREM2 in early stages of disease highlights the importance of context and stage of disease when defining molecular mechanisms and identifying therapeutic targets.”
Marongiu, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00242 · Cited by 42
“…(Frautschy et al., 1998; Benzing et al., 1999; Parachikova et al., 2007; Kraft et al., 2013; Christensen and Pike, 2015; Heneka et al., 2015; Matarin et al., 2015; Au et al., 2016; Song et al., 2016; Villa et al., 2016; Wang et al., 2016; Czirr et al., 2017; Jevtic et al., 2017; Liu et al., 2017).”
Does soluble TREM2 protect against Alzheimer's disease?
Brown, G. C., & St George-Hyslop, P. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.834697 · Cited by 39
Da Mesquita, S., & Rua, R. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.03.007 · Cited by 41
Dysregulated Brain Cholesterol Metabolism Is Linked to Neuroinflammation in Huntington's Disease
González‐Guevara, E., Cárdenas, G., Pérez‐Severiano, F., & Martínez‐Lazcano, J. C. (2020) · Movement Disorders · doi:10.1002/mds.28089 · Cited by 42
Dvir-Szternfeld, R., Castellani, G., Arad, M., Cahalon, L., Colaiuta, S. P., Keren-Shaul, H., Croese, T., Burgaletto, C., Baruch, K., Ulland, T., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00149-w · Cited by 44
Self-citationMicroglia degrade Alzheimer’s amyloid-beta deposits extracellularly via digestive exophagy
Jacquet, R. G., González Ibáñez, F., Picard, K., Funes, L., Khakpour, M., Gouras, G. K., Tremblay, M.-È., Maxfield, F. R., & Solé-Domènech, S. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.115052 · Cited by 42
Yang, S., Magnutzki, A., Alami, N. O., Lattke, M., Hein, T. M., Scheller, J. S., Kröger, C., Oswald, F., Yilmazer‐Hanke, D., Wirth, T., et al. (2021) · Cells · doi:10.3390/cells10102669 · Cited by 44
“Vice versa and supporting this view, deficits in inflammation-associated processes involved in Aβ clearance are increasingly recognized as crucial events in AD pathogenesis [47,48,60,84,85].”
BackgroundKumar, S., Budhathoki, S., Oliveira, C. B., Kahle, A. D., Calhan, O. Y., Lukens, J. R., & Deppmann, C. D. (2023) · JCI Insight · doi:10.1172/jci.insight.157433 · Cited by 39
“exhibited diminished plaque burden, it would appear that the reduced microglial activation/plaque interaction may be beneficial in this setting in contrast to other cases, such as with TREM2 loss, which leads to increased plaque load and worsening of cognitive function (37, 38).”
ResultRoles of TREM2 in the Pathological Mechanism and the Therapeutic Strategies of Alzheimer's Disease
Lin, M., Yu, J., Zhang, W., Lao, F., & Huang, H. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.164 · Cited by 48
The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy
Cisternas, P., Taylor, X., & Lasagna‐Reeves, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246319 · Cited by 44
Henningfield, C. M., Arreola, M. A., Soni, N., Spangenberg, E. E., & Green, K. N. (2022) · Glia · doi:10.1002/glia.24105 · Cited by 40
“Previous studies have shown that global Trem2 or Apoe knock-out decreases plaque-associated microgliosis in multiple mouse models of AD (Bales et al., 1999; Jay et al., 2017; Krasemann et al., 2017; Meilandt et al., 2020; Wang et al., 2016) which is not seen with the model used in this study.”
ResultDas, M., Mao, W., Voskobiynyk, Y., Necula, D., Lew, I., Petersen, C., Zahn, A., Yu, G.-Q., Yu, X., Smith, N., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106263 · Cited by 41
SELENOK-dependent CD36 palmitoylation regulates microglial functions and Aβ phagocytosis
Ouyang, P., Cai, Z., Peng, J., Lin, S., Chen, X., Chen, C., Feng, Z., Wang, L., Song, G.-L., & Zhang, Z. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103064 · Cited by 45
“Indeed, microglial activation is implicated in the early stages of AD, contributing to A β clearance and degradation [27 – 29].”
BackgroundNeuroinflammation of Microglial Regulation in Alzheimer’s Disease: Therapeutic Approaches
Chen, H., Zeng, Y., Wang, D., Li, Y., Xing, J., Zeng, Y., Liu, Z., Zhou, X., & Fan, H. J. (2024) · Molecules · doi:10.3390/molecules29071478 · Cited by 46
Liu, P., Reichl, J. H., Rao, E. R., McNellis, B. M., Huang, E. S., Hemmy, L. S., Forster, C. L., Kuskowski, M. A., Borchelt, D., Vassar, R. J., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-161027 · Cited by 45
The role of TREM2 in Alzheimer's disease; evidence from transgenic mouse models
Karanfilian, L., Tosto, M. G., & Malki, K. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.004 · Cited by 41
Takata, K., Ginhoux, F., & Shimohama, S. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114754 · Cited by 45
Feiten, A. F., Dahm, K., Schlepckow, K., van Lengerich, B., Suh, J. H., Reifschneider, A., Wefers, B., Bartos, L. M., Wind-Mark, K., de Weerd, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-68706-8 · Cited by 39
“Variants of TREM2 are associated with increased risk for late-onset AD, and the paper aims to better understand the molecular and functional changes that occur in microglia when TREM2 is either upregulated or downregulated.”
Chen, Y., Hong, T., Chen, F., Sun, Y., Wang, Y., & Cui, L. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631827 · Cited by 38
Self-citationTPM1 mediates inflammation downstream of TREM2 via the PKA/CREB signaling pathway
Li, R., Zhang, J., Wang, Q., Cheng, M., & Lin, B. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02619-3 · Cited by 45
Dual roles of Aβ in proliferative processes in an amyloidogenic model of Alzheimer’s disease
Baglietto-Vargas, D., Sánchez-Mejias, E., Navarro, V., Jimenez, S., Trujillo-Estrada, L., Gómez-Arboledas, A., Sánchez-Mico, M., Sánchez-Varo, R., Vizuete, M., Dávila, J. C., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10353-7 · Cited by 38
Ruiz‐Pérez, G., Esteban, S. R. D. M., Marqués, S., Aparicio, N., Grande, M. T., Benito‐Cuesta, I., Martínez-Relimpio, A. M., Arnanz, M. A., Tolón, R. M., Posada-Ayala, M., et al. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02276-y · Cited by 42
INPP5D modulates TREM2 loss-of-function phenotypes in a β-amyloidosis mouse model
Iguchi, A., Takatori, S., Kimura, S., Muneto, H., Wang, K., Etani, H., Ito, G., Sato, H., Hori, Y., Sasaki, J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106375 · Cited by 42
Huang, Y., Guimarães, T. R., Todd, N., Ferguson, C., Weiss, K. M., Stauffer, F., McDermott, B., Hurtle, B. T., Saito, T., Saido, T. C., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2204828119 · Cited by 38
Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development
Biber, K., Bhattacharya, A., Campbell, B. M., Piro, J. R., Rohe, M., Staal, R. G. W., Talanian, R. V., & Möller, T. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00840 · Cited by 41
Microglial TREM2 at the Intersection of Brain Aging and Alzheimer’s Disease
Qu, W., & Li, L. (2021) · The Neuroscientist · doi:10.1177/10738584211040786 · Cited by 40
Wan, T., Fu, M., Jiang, Y., Jiang, W., Li, P., & Zhou, S. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03448-1 · Cited by 40
Ma, C., Wu, Y., Song, L., Yin, L., Yin, J.-J., Wang, Q., Yu, J., & Xiao, B. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.355747 · Cited by 39
“…Aβ levels, slows down the formation of SP, and prevents the generation of NFT in patients with only pathophysiological changes of AD but without or only mild clinical symptoms, all of which contribute markedly to stopping the onset and delaying the clinical progression of AD (Wang et al., 2016).”
BackgroundRoles of TREM2 in Alzheimer’s disease
Qi, X., Zhu, K., Ke, W., Wang, J., Mao, S., & Chen, G. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00515-3 · Cited by 42
“4a) [141, 168, 176].”
Functional diversity of disorder-specific macrophages involved in various diseases
Mitsui, Y., & Satoh, T. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00390-5 · Cited by 41
“In the early stages of AD, DAMs help remove toxic aggregates and maintain CNS homeostasis [92, 93].”
The Ambiguous Role of Microglia in Aβ Toxicity: Chances for Therapeutic Intervention
Merlo, S., Spampinato, S. F., Caruso, G. I., & Sortino, M. A. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200131105418 · Cited by 37
Lim, S., Rodríguez‐Ortiz, C. J., Hsu, H.-W., Wu, J., Zumkehr, J., Kilian, J., Vidal, J., Ayata, P., & Kitazawa, M. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126578 · Cited by 35
“These findings highlight the critical role of microglia and their contribution to the AD pathology as shown in recent emerging evidence [31-34].”
BackgroundAn overview of microglia ontogeny and maturation in the homeostatic and pathological brain
Mendes, M. S., & Majewska, A. K. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15225 · Cited by 39
“In addition to complement, TREM2, a cell surface receptor expressed in myeloid cells, including microglia, was shown to modulate inflammation and phagocytosis in AD (Wang et al., 2016).”
BackgroundAlthafar, Z. M. (2022) · Molecules · doi:10.3390/molecules27134124 · Cited by 35
Shastri, D., Raj, V., & Lee, S.-K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102379 · Cited by 36
Belloli, S., Pannese, M., Buonsanti, C., Maiorino, C., Di Grigoli, G., Carpinelli, A., Monterisi, C., Moresco, R. M., & Panina-Bordignon, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.010 · Cited by 34
Diabetic phenotype in mouse and humans reduces the number of microglia around β-amyloid plaques
Natunen, T., Martiskainen, H., Marttinen, M., Gabbouj, S., Koivisto, H., Kemppainen, S., Kaipainen, S., Takalo, M., Svobodová, H., Leppänen, L., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00415-2 · Cited by 35
“Furthermore, the area of dystrophic neurites was assessed around β-amyloid plaques in HC with 22C11 antibody, which is another well-established option to detect dystrophic neurites [66] (Supplementary Fig.”
BackgroundSokolova, D., Childs, T., & Hong, S. Y. (2021) · Faculty Reviews · doi:10.12703/r/10-19 · Cited by 39
Lecordier, S., Pons, V., Rivest, S., & ElAli, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.813536 · Cited by 37
“Accumulation of Ab in the brain triggers microglial cell activation, which plays a double-edged sword in AD pathology (13), by promoting neuronal protection at the early stages via Ab clearance (14, 15), and to neuronal loss at the advanced stages via release of neurotoxic and pro-inflammatory factors leading to chron…”
BackgroundThe emerging role of brain neuroinflammatory responses in Alzheimer’s disease
AmeliMojarad, M., AmeliMojarad, M., & Cui, X. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1391517 · Cited by 40
Konishi, H., & Kiyama, H. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104878 · Cited by 34
Cholesterol signaling in single cells: lessons from STAR and sm-FISH
Jefcoate, C. R. E., & Lee, J. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-17-0281 · Cited by 34
Lymphoid gene expression supports neuroprotective microglia function
Ayata, P., Crowley, J. M., Challman, M. F., Sahasrabuddhe, V., Gratuze, M., Werneburg, S., Ribeiro, D., Hays, E. C., Durán-Laforet, V., Faust, T. E., et al. (2025) · Nature · doi:10.1038/s41586-025-09662-z · Cited by 32
Self-citationScott‐Hewitt, N., Folts, C. J., Hogestyn, J. M., Piester, G., Mayer-Pröschel, M., & Noble, M. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx153 · Cited by 33
Biological correlates of elevated soluble TREM2 in cerebrospinal fluid
Winfree, R. L., Dumitrescu, L., Blennow, K., Zetterberg, H., Gifford, K. A., Pechman, K. R., Jefferson, A. L., & Hohman, T. J. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.06.013 · Cited by 31
“More specifically, functional studies of TREM2 have revealed roles in the regulation of parenchymal Aβ plaque deposition (Jay et al. 2017; Kober et al. 2020; Song et al. 2018; Ulland et al. 2017; Wang et al. 2015; Wang et al. 2016; Yuan et al. 2016), progression of tau pathology (Bemiller et al.”
BackgroundLuo, Q., Schnöder, L., Hao, W., Litzenburger, K., Decker, Y., Tomic, I., Menger, M. D., Fassbender, K. C., & Liu, Y. (2022) · Aging Cell · doi:10.1111/acel.13679 · Cited by 36
The role of TREM2 N-glycans in trafficking to the cell surface and signal transduction of TREM2
Shirotani, K., Hatta, D., Wakita, N., Watanabe, K., & Iwata, N. (2022) · The Journal of Biochemistry · doi:10.1093/jb/mvac073 · Cited by 33
Tobeh, N. S., & Bruce, K. D. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1259012 · Cited by 38
“TREM2 deficiencies also equate to reduced microglial proliferation and survival (Wang et al., 2016; Zheng et al., 2017; Gratuze et al., 2018).”
BackgroundTREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
Zheng, J., Wang, L., Zhao, S., Zhang, W., Chang, Y., Bosco, D. B., Huang, T., Dheer, A., Gao, S., Xu, S., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad214 · Cited by 35
Li, L., Wang, L., & Zhang, L. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c07536 · Cited by 35
Erythromyeloid-Derived TREM2: A Major Determinant of Alzheimer’s Disease Pathology in Down Syndrome
Raha-Chowdhury, R., Henderson, J. W., Raha, A. A., Stott, S. R. W., Vuono, R., Foscarin, S., Wilson, L., Annus, T., Fincham, R., Allinson, K., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170814 · Cited by 31
Hernández, E. R., Sánchez-Maldonado, C., Chávez, M. Á. M., Hernández-Zimbrón, L. F., Patricio-Martínez, A., Zenteno, E., & Limón, I. D. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1750955 · Cited by 35
Fujita, Y., Kano, K., Kishino, S., Nagao, T., Shen, X., Sato, C., Hatakeyama, H., Ota, Y., Niibori, S., Nomura, A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88870-9 · Cited by 37
Metadata
- Authors
- Wang, Y., Ulland, T. K., Ulrich, J. D., Song, W., Tzaferis, J. A., Hole, J. T., Yuan, P., Mahan, T. E., Shi, Y., Gilfillan, S., Cella, M., Grutzendler, J., DeMattos, R. B., Cirrito, J. R., Holtzman, D. M., & Colonna, M.
- Affiliations
- Eli Lilly (United States) (US)
- Washington University in St. Louis (US)
- Yale University (US)
- Corresponding author
- Colonna, Marco
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2016-04-18
- Volume
- 213
- Issue
- 5
- Pages
- 667-675
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4854736
- OpenAlex
- W2339534121
- Cited by
- 840
- References
- 32
- Citations by year
- 2026: 62 · 2025: 76 · 2024: 86 · 2023: 106 · 2022: 114 · 2021: 102 · 2020: 93 · 2019: 73 · 2018: 61 · 2017: 50 · 2016: 16
- FWCI
- 36.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- Eli Lilly and Company
- National Institutes of Health (RF1 AG05148501, 5T32CA009547-30, AG047644)
- National Multiple Sclerosis Society (RG4687A1/1)
- Cure Alzheimer’s Fund
- JPB Foundation
- Knight Alzheimer’s Disease Research Center (P50 AG005681-30)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
- Keywords
- TREM2, microglia, amyloid plaques, Alzheimer's disease, parabiosis, 5xFAD mice, TREM2 deficiency, lipid microenvironment, peripheral blood monocytes
- MeSH terms
- Alzheimer Disease, Animals, Disease Models, Animal, Humans, Membrane Glycoproteins, Monocytes, Receptors, Immunologic, Amyloid beta-Peptides, Neurites, Microglia, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.